Scarica l'app Stockscreener
17.56
1.13%
-0.20
Dopo l'orario di chiusura:
17.65
0.09
+0.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$17.76
Aprire:
$17.65
Volume 24 ore:
14.61M
Relative Volume:
1.37
Capitalizzazione di mercato:
$20.45B
Reddito:
$14.57B
Utile/perdita netta:
$-296.50M
Rapporto P/E:
-67.80
EPS:
-0.259
Flusso di cassa netto:
$1.64B
1 W Prestazione:
+1.86%
1M Prestazione:
+10.58%
6M Prestazione:
+34.15%
1 anno Prestazione:
+100.92%
Intervallo 1D:
$17.38
$17.69
Intervallo di 1 settimana:
$17.28
$18.07
Portata 52W:
$8.625
$18.07
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.56 | 20.54B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris Inc (VTRS) Income Statement - TradingKey
Viatris Inc (VTRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris stock hits 52-week high at $17.68 - Investing.com
Viatris Inc (VTRS) Cash Flow - TradingKey
VTRS|Viatris Inc|Price:17.635|Chg%:+0.395 - TradingKey
Viatris, Inc. Revenue Breakdown – BX:VTRS - TradingView
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc. Revenue Breakdown – NASDAQ:VTRS - TradingView
Viatris, Inc. (VTRS) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris, Inc. (VTRS) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
PFE5282054 Bond Profile — Key Metrics - TradingView
Viatris, Inc. (VTRS) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris, Inc. Revenue Breakdown – LSX:A2QAME - TradingView
Viatris Inc (VTRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
PFE5003244 Bond Profile — Key Metrics - TradingView
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
PFE5282056 Bond Profile — Key Metrics - TradingView
Viatris Inc (VTRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris, Inc. (VIA) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Viatris, Inc. (VIA) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris, Inc. (VIA) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Viatris, Inc. (VIA) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Viatris, Inc. (1VTRS) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
PFE5003242 Bond Profile — Key Metrics - TradingView
Khaitan & Co Advised Viatris Inc. On Secondary Sale Of Shares Held in Biocon - BW Legal World
Is Viatris (VTRS) Reframing Its Musculoskeletal Strategy Through the AAOS Pain Management Partnership? - Sahm
Viatris stock hits 52-week high at $17.54 By Investing.com - Investing.com South Africa
Viatris stock hits 52-week high at $17.54 - Investing.com UK
Khaitan & Co, JSA, TT&A, Baker & McKenzie act on Viatris Inc's ₹3,680 crore exit from Biocon - Bar and Bench
PFE5282058 Bond Profile — Key Metrics - TradingView
Viatris Inc (VTRS) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Looks to New Launches and Cost Savings for Long-Term Growth - Morningstar
XS332542958 Bond Profile — Key Metrics - TradingView
ETFs Investing in Viatris, Inc. Stocks - TradingView
Mylan to sell up to $363 million stake in India’s Biocon, term sheet shows - WTVB
Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon - Business Standard
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows - Reuters
(VTRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viatris shares break six-session winning streak - MSN
BofA Securities Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.08%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):